This data is consistent with existing studies that have examined the interactions between PTEN and AR in breast and prostate cancer showing that PTEN and AR directly interact and that loss of PTEN, and commensurate increased PI3K activity, reduces AR signaling [50,51,52]. This evidence concerns the gene AR and prostate carcinoma.